Preclinical Embolic Stroke Research Services

Embolic strokes are classified as a type of ischemic stroke. An embolic stroke happens when a blood clot that forms in another part of the body dislodges and travels through the bloodstream to the brain. When this clot becomes lodged in a cerebral artery, it obstructs blood flow, leading to a stroke. Blood clots that can cause embolic strokes may develop in various locations. Typically, they originate from the heart or the arteries located in the upper chest and neck regions. Treatment of embolic stroke usually includes administration of tissue plasminogen activator, carotid endarterectomy, mechanical clot removal. However, these approaches have their limitations. Further research is essential to identify potential sources of embolism and to develop innovative therapies.

Fig. 1. Optimizing clot length to establish a dependable eMCAO model in mice. Fig. 1 Optimization of clot length to produce a reliable eMCAO model in mice. (Wang, et al., 2022)

As a leading global stroke research service provider, Ace Therapeutics offers comprehensive preclinical research services focused on embolic stroke. Utilizing our expertise in translational research, we provide an extensive array of services, animal models, and tailored approaches to deliver exceptional preclinical support for your program.

Custom Animal Models of Embolic Stroke

Our preclinical research capabilities in embolic stroke encompass the leading animal models crucial for drug discovery and development. We provide macrosphere models-animal models of focal brain ischemia, where titanium dioxide (TiO₂) is injected into the internal carotid artery. Additionally, we can induce embolic middle cerebral artery occlusion (MCAO) using clots of varying sizes that are formed from thrombin and fibrinogen.

These models allow us to assist clients in uncovering the underlying mechanisms of embolic strokes and developing innovative therapeutics.

Types of Drugs We Can Develop for Embolic Stroke

Antiplatelet Drugs

Anticoagulants

Preclinical Evaluation of Embolic Stroke Therapies

Our team of experts is committed to helping clients analyze the spatiotemporal dynamics of cerebral blood flow and metabolism, neuroinflammation, cortical spreading depolarizations, and stem cell-mediated regeneration during embolic stroke. Our goal is to accelerate the development of innovative therapeutics for embolic stroke.

Preclinical Evaluation Services	Service Details
Monitoring of cerebral blood flow and metabolism	Evaluate the early spatio-temporal development of cerebral blood flow and metabolism in the embolic model using positron emission tomography (PET), the radiotracers [¹⁵O]H₂O, and [¹⁸F]-2-fluoro-2-deoxy-D-glucose (FDG).
Measurement of cerebral edema	Explore the progression of ischemia in an embolic stroke model using magnetic resonance imaging (MRI). Clarify the development of cytotoxic and vasogenic cerebral edema during the hyperacute phase of stroke.
Analysis of cortical spreading depolarizations (CSD)	Investigate changes in regional cerebral blood flow (rCBF) during and after MCAO in embolic stroke models using laser speckle contrast imaging.
Neuroinflammation analysis	Investigate neuroinflammation in the embolic stroke model using a multimodal imaging protocol, including T2-weighted MRI and PET with the radiotracers [¹¹C] PK11195 and [¹⁸F] FDG. Offer immunohistopathology services to characterize the spatial and temporal aspects of cell-mediated neuroinflammation.
Stem cell-mediated regeneration studies	Provide imaging assays using PET with the radiotracer 3'-deoxy-3'-[¹⁸F] fluoro-l-thymidine to monitor the mobilization of endogenous NSC in the brains of animal models following embolic stroke. Identify therapeutic agents that have the potential to improve NSC survival and/or proliferation.

Collaborate with Ace Therapeutics to enhance your understanding of the pathogenesis of embolic stroke and drive forward your groundbreaking therapeutic innovations. Our extensive experience and customized models empower us to provide comprehensive preclinical embolic stroke research services. If you are interested in our services, please contact us for more information.

References

Walberer, M., & Rueger, M. A. (2015). The macrosphere model-an embolic stroke model for studying the pathophysiology of focal cerebral ischemia in a translational approach. Annals of Translational Medicine, 3(9).
Wang, R., et al. (2022). Optimized mouse model of embolic MCAO: From cerebral blood flow to neurological outcomes. Journal of Cerebral Blood Flow & Metabolism, 42(3), 495-509.

All of our services are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.